• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Large owner Baskett Forest

    10/3/24 6:20:10 PM ET
    $NEUE
    Medical Specialities
    Health Care
    Get the next $NEUE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    BASKETT FOREST

    (Last) (First) (Middle)
    2855 SAND HILL ROAD

    (Street)
    MENLO PARK CA 94025

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    NeueHealth, Inc. [ NEUE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/01/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Warrant (Right to Buy) $0.01 10/01/2024 P 61,865 10/02/2024 04/30/2029 Common Stock 61,865 (1) 185,594 I See Note 2(2)
    Warrant (Right to Buy) $0.01 10/01/2024 P 61,865 10/02/2024 04/30/2029 Common Stock 61,865 (1) 185,594 I See Note 3(3)
    Warrant (Right to Buy) $0.01 10/01/2024 P 61,865 10/02/2024 04/30/2029 Common Stock 61,865 (1) 185,594 I See Note 4(4)
    Explanation of Responses:
    1. Warrants issued pursuant to the Warrantholders Agreement, dated April 8, 2024, between the Issuer and the holders listed on Schedule 1 thereto, and the Credit Agreement, dated August 4, 2023, as amended by that certain Incremental Amendment No. 1, dated as of October 2, 2023, and that certain Incremental Amendment No. 2, dated as of April 8, 2024, between the Issuer and the lenders thereto.
    2. The Reporting Person is a manager of NEA 15 GP, LLC, which is the sole general partner of NEA Partners 15, L.P. ("NEA Partners 15"). NEA Partners 15 is the sole general partner of New Enterprise Associates 15, L.P. ("NEA 15"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 15 in which the Reporting Person has no pecuniary interest.
    3. The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.
    4. The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.
    /s/ Zachary Bambach, attorney-in-fact 10/03/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NEUE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEUE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Matushak Jay returned 40,431 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NeueHealth, Inc. (0001671284) (Issuer)

    10/14/25 7:54:57 PM ET
    $NEUE
    Medical Specialities
    Health Care

    Large owner Bessemer Venture Partners Ix L.P. returned 999,218 shares to the company (SEC Form 4)

    4 - NeueHealth, Inc. (0001671284) (Issuer)

    10/6/25 7:45:32 PM ET
    $NEUE
    Medical Specialities
    Health Care

    Director Kraus Stephen returned 16,443 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - NeueHealth, Inc. (0001671284) (Issuer)

    10/6/25 7:35:04 PM ET
    $NEUE
    Medical Specialities
    Health Care

    $NEUE
    SEC Filings

    View All

    SEC Form 15-12G filed by NeueHealth Inc.

    15-12G - NeueHealth, Inc. (0001671284) (Filer)

    10/14/25 6:02:35 AM ET
    $NEUE
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by NeueHealth Inc.

    SCHEDULE 13D/A - NeueHealth, Inc. (0001671284) (Subject)

    10/6/25 5:00:02 PM ET
    $NEUE
    Medical Specialities
    Health Care

    SEC Form S-8 POS filed by NeueHealth Inc.

    S-8 POS - NeueHealth, Inc. (0001671284) (Filer)

    10/2/25 11:02:08 AM ET
    $NEUE
    Medical Specialities
    Health Care

    $NEUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NeueHealth Announces Closing of Take-Private Transaction

    NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today announced the successful closing of its previously announced merger under which NeueHealth has been acquired by an affiliate of New Enterprise Associates ("NEA") at an enterprise value of approximately $1.465 billion. Under the terms of the merger agreement, holders of NeueHealth common stock (other than shares that will be rolled over and certain excluded shares) will receive $7.33 per share in cash. Certain stockholders of NeueHeath, including NEA and 12 existing NeueHealth investors (which collectively hold all of the outstanding shares of NeueHealth preferred stock), have entered i

    10/2/25 9:16:00 AM ET
    $NEUE
    Medical Specialities
    Health Care

    NeueHealth Reports Second Quarter 2025 Results

    Delivered strong second quarter financial results, reflecting the continued success of consumer-centric care model and ability to create value for consumers, payors, and providers across the industry Drove positive Adjusted EBITDA for the sixth consecutive quarter, placing the company in a strong position to drive long-term, sustainable growth this year and beyond Served approximately 694,000 consumers, an increase of 45% over the second quarter of 2024 NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial results for its second quarter ended June 30, 2025. "We are pleased to report another strong quarter of f

    8/7/25 6:45:00 AM ET
    $NEUE
    Medical Specialities
    Health Care

    NeueHealth to Host Second Quarter 2025 Earnings Conference Call on August 7, 2025

    NeueHealth, Inc. ("NeueHealth") (NYSE:NEUE), the value-driven healthcare company, today announced it will report second quarter financial results before the financial markets open on Thursday, August 7, 2025, followed by a conference call at 8:00 AM Eastern Time. To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call. A webcast of the earnings call may also be accessed via NeueHealth's Investor Relations page at investors.neuehealth.com. The company suggests parti

    7/17/25 8:00:00 AM ET
    $NEUE
    Medical Specialities
    Health Care

    $NEUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by NeueHealth Inc. (Amendment)

    SC 13D/A - NeueHealth, Inc. (0001671284) (Subject)

    4/10/24 9:52:09 PM ET
    $NEUE
    Medical Specialities
    Health Care

    $NEUE
    Financials

    Live finance-specific insights

    View All

    NeueHealth Reports Second Quarter 2025 Results

    Delivered strong second quarter financial results, reflecting the continued success of consumer-centric care model and ability to create value for consumers, payors, and providers across the industry Drove positive Adjusted EBITDA for the sixth consecutive quarter, placing the company in a strong position to drive long-term, sustainable growth this year and beyond Served approximately 694,000 consumers, an increase of 45% over the second quarter of 2024 NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial results for its second quarter ended June 30, 2025. "We are pleased to report another strong quarter of f

    8/7/25 6:45:00 AM ET
    $NEUE
    Medical Specialities
    Health Care

    NeueHealth to Host Second Quarter 2025 Earnings Conference Call on August 7, 2025

    NeueHealth, Inc. ("NeueHealth") (NYSE:NEUE), the value-driven healthcare company, today announced it will report second quarter financial results before the financial markets open on Thursday, August 7, 2025, followed by a conference call at 8:00 AM Eastern Time. To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call. A webcast of the earnings call may also be accessed via NeueHealth's Investor Relations page at investors.neuehealth.com. The company suggests parti

    7/17/25 8:00:00 AM ET
    $NEUE
    Medical Specialities
    Health Care

    NeueHealth Reports First Quarter 2025 Results

    Delivered strong first quarter performance as care model continues to resonate with consumers, providers, and payors across the healthcare industry Drove positive Adjusted EBITDA for the fifth consecutive quarter, providing a strong foundation for continued success in 2025 and beyond Served approximately 709,000 consumers, an increase of 51% over the first quarter of 2024 NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial results for its first quarter ended March 31, 2025. "We are starting 2025 in a very strong position, generating substantial growth in the number of consumers we serve and delivering another

    5/8/25 6:45:00 AM ET
    $NEUE
    Medical Specialities
    Health Care